Currently available treatment with proven outcomes Semaglutide FDA-approved for diabetes (Ozempic), obesity (Wegovy), and CV risk reduction with 7+ years of clinical and post-marketing data Cardiovascular risk reduction Semaglutide SELECT trial demonstrated 20% MACE reduction in 17,604 patients -- the first anti-obesity drug with proven cardiovascular benefit Maximum weight loss potential Retatrutide Phase 2 data showed 24.2% weight loss at 48 weeks with weight curves still declining, though Phase 3 confirmation is required Metabolic liver disease (MASLD/MASH) Retatrutide Glucagon receptor agonism directly promotes hepatic fat oxidation, a mechanistic advantage for liver-specific outcomes Oral administration preference Semaglutide Only incretin-class drug available as an oral tablet (Rybelsus), with higher-dose oral formulations under development Type 2 diabetes with established treatment guidelines Semaglutide Integrated into clinical guidelines with multiple approved doses and formulations, extensive comparative data, and guideline positioning Continue Your Research Get comparison updates We publish new head-to-head comparisons regularly
The impact of dabigatran treatment on sinusoidal protection against hepatic ischemia/reperfusion injury in mice
Carnitine deficiency can lead to a myriad of health issues, including muscle weakness, fatigue, and heart complications
Suspected adverse reactions to any medicine or unlicensed product should be reported via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk)
The platform provides the depth of research and practical guidance needed to navigate the complex landscape of weight loss peptides with confidence
Deviating from this schedule without medical supervision could alter absorption rates, side effect profiles, and overall efficacy
